TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.

医学 临床研究阶段 癌症 人口 临床终点 伊立替康 内科学 肿瘤科 癌症研究 毒性 临床试验 环境卫生 结直肠癌
作者
Ashish Saxena,Loren S. Michel,Hong Qin,Karrie Hilsinger,Charu Kanwal,Cabilia Pichardo,Trishna Goswami,Alessandro D. Santin
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:38 (15_suppl): TPS3648-TPS3648 被引量:2
标识
DOI:10.1200/jco.2020.38.15_suppl.tps3648
摘要

TPS3648 Background: Trophoblast cell surface antigen (Trop-2) is highly expressed in many epithelial cancers (non–small-cell lung cancer [NSCLC], endometrial cancer, urothelial carcinoma [UC], and triple-negative breast cancer [TNBC]) and has been linked to aggressive disease and poor prognosis. SG is a Trop-2–directed antibody drug conjugate containing SN-38 (active metabolite of irinotecan) with a 7.5:1 drug-to-antibody ratio and unique hydrolyzable linker that allows for extracellular bystander effect. The phase 1/2 IMMU-132-01 basket study reported clinical activity with SG in patients with multiple tumor types not selected for Trop-2 expression including NSCLC (objective response rate [ORR]: 17%), TNBC (ORR: 33%), and UC (ORR: 31%).1-3 Results from the overall safety population (N=420) from this study found that SG was tolerable, with a predictable and manageable safety profile, and low discontinuation rates due to AEs. Methods: To test a biomarker-enrichment strategy with Trop-2, the TROPiCS-03 (TROP-2 Investigations in Cancer with SG) study was initiated. TROPiCS-03 (NCT03964727) is a multi-cohort, open-label, phase 2 study in patients with metastatic solid tumors - presently NSCLC (adenocarcinoma and squamous cell carcinoma), head and neck squamous cell carcinoma, and endometrial cancer - selected based on elevated Trop-2 expression by a validated IHC assay. Patients receive SG (10 mg/kg IV, days 1 and 8 every 21 days) and continue treatment until lack of clinical benefit or unacceptable toxicity. The primary endpoint is objective response rate (local assessment) and additional endpoints include clinical benefit rate, duration of response, progression-free survival, and safety. Females or males ≥18 years old who are histologically documented to have locally advanced or metastatic (M1, stage 4) solid tumors of the above types are eligible. Patients must have ECOG 0 or 1 and adequate clinical laboratory results to be enrolled. All subjects will have progressed after prior platinum-based chemotherapy and programmed death-ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1) directed therapy. Patients who have previously received topoisomerase I inhibitors and those with known active CNS metastases are excluded. Approximately 160 patients will be enrolled in the trial overall; enrollment in the NSCLC cohort is currently in progress. References: Heist RS et al. J Clin Oncol. 2017;35:2790-7, Bardia A et al., NEJM. 2019;380:741-51.,Tagawa ST et al., Oral presentation; ASCO-GU 2019, San Francisco, CA. Clinical trial information: NCT03964727 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明哲派完成签到,获得积分10
刚刚
1秒前
淡淡哈密瓜完成签到,获得积分10
1秒前
3秒前
研友_VZG7GZ应助小乌龟采纳,获得10
7秒前
7秒前
7秒前
Hanson发布了新的文献求助10
8秒前
可爱的函函应助高高采纳,获得10
8秒前
sugus发布了新的文献求助10
8秒前
9秒前
香蕉觅云应助李圳铭采纳,获得10
9秒前
lin完成签到,获得积分10
11秒前
mera发布了新的文献求助10
11秒前
静穆儿完成签到,获得积分10
11秒前
12秒前
Hello应助东哥采纳,获得10
13秒前
小马甲应助YE采纳,获得10
14秒前
机智的小天才完成签到,获得积分10
14秒前
14秒前
Sun发布了新的文献求助10
14秒前
15秒前
青枝发布了新的文献求助30
17秒前
踏雪寻梅举报田七的茄子求助涉嫌违规
17秒前
李健的小迷弟应助七块采纳,获得10
17秒前
丁真先生发布了新的文献求助20
19秒前
19秒前
量子发布了新的文献求助10
19秒前
SKD完成签到 ,获得积分10
20秒前
肖肖肖完成签到 ,获得积分10
20秒前
21秒前
21秒前
小乌龟发布了新的文献求助10
21秒前
LH完成签到 ,获得积分10
21秒前
22秒前
兴奋元冬完成签到,获得积分10
23秒前
香草山完成签到 ,获得积分10
24秒前
华仔应助你是千堆雪采纳,获得10
24秒前
宸延完成签到,获得积分10
24秒前
秀丽绮玉发布了新的文献求助10
25秒前
高分求助中
中央政治學校研究部新政治月刊社出版之《新政治》(第二卷第四期) 1000
Hopemont Capacity Assessment Interview manual and scoring guide 1000
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
Mantids of the euro-mediterranean area 600
【港理工学位论文】Telling the tale of health crisis response on social media : an exploration of narrative plot and commenters' co-narration 500
Mantodea of the World: Species Catalog Andrew M 500
Insecta 2. Blattodea, Mantodea, Isoptera, Grylloblattodea, Phasmatodea, Dermaptera and Embioptera 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 基因 遗传学 化学工程 复合材料 免疫学 物理化学 细胞生物学 催化作用 病理
热门帖子
关注 科研通微信公众号,转发送积分 3434089
求助须知:如何正确求助?哪些是违规求助? 3031323
关于积分的说明 8941651
捐赠科研通 2719262
什么是DOI,文献DOI怎么找? 1491703
科研通“疑难数据库(出版商)”最低求助积分说明 689427
邀请新用户注册赠送积分活动 685580